Evidence map›Paper›PMID 22503967›Full record

ArticlePharmacology, biochemistry, and behavior2012

Enhanced attenuation of nicotine discrimination in rats by combining nicotine-specific antibodies with a nicotinic receptor antagonist.

Mark G LeSage, David Shelley, Marco Pravetoni, Paul R Pentel

Open access · greenAbstract read
In one paragraph

Article in Pharmacology, biochemistry, and behavior, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Effects of the Nanoparticle-Based Vaccine, SEL-068, on Nicotine Discrimination in Squirrel Monkeys.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2015
    Article
  8. Article
  9. Article
  10. New directions in nicotine vaccine design and use.Advances in pharmacology (San Diego, Calif.) · 2014
    Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Mark G LeSageDepartment of Medicine, Minneapolis Medical Research Foundation, Minneapolis, MN, United States. lesag002@umn.edu
David Shelley
Marco Pravetoni
Paul R Pentel
University of Minnesota · USOrthopaedic Research Foundation · US

Funding

IMMUNIZATION TO BLOCK THE EFFECTS OF NICOTINER01DA010714 · NIDA · MINNEAPOLIS MEDICAL RESEARCH FDN, INC. · PI PENTEL, PAUL R · 1997 to 2012
$5.7M
NIDA NIH HHS DA-10714NIDA NIH HHS R01 DA010714
6 · The paper itself

Abstract

Tobacco addiction requires activation by nicotine of a variety of central nicotinic acetylcholine receptors (nAChRs). In animals, both nAChR antagonists and immunization against nicotine can reduce nAChR activation by nicotine and block a variety of addiction-relevant behaviors. However, clinical use of nAChR antagonists for smoking cessation is limited by dose-related side effects, and immunization does not reliably produce sufficient antibody levels in smokers to enhance smoking cessation rates. Combining these approaches may be one way of addressing the limitations of each while enhancing overall efficacy. This study examined the individual and combined effects of passive immunization with the monoclonal nicotine-specific antibody Nic311 and the nicotinic receptor antagonist mecamylamine (MEC) on nicotine's discriminative stimulus effects. Rats were trained to discriminate 0.4 mg/kg of nicotine from saline using a two-lever operant discrimination procedure. Antagonism of nicotine discrimination by Nic311 (160 mg/kg i.v.) and ascending doses of MEC (0.03, 0.1, 0.3, and 1.0 mg/kg s.c.) was assessed across four consecutive daily 2-min extinction test sessions using a 2×2 design. Nic311 alone produced a 24-48% reduction in % nicotine-lever responding (%NLR) across all four test sessions. MEC produced a dose-dependent decrease in %NLR, with no effect at the two lowest doses and 80-93% attenuation at the two highest doses. Nic311 combined with MEC significantly suppressed %NLR at every MEC dose (85-92% reduction across all four test sessions). Very low doses of MEC that were ineffective alone completely blocked nicotine discrimination when combined with Nic311. These data demonstrate that nicotine-specific antibodies and MEC can work synergistically to suppress the subjective effects of nicotine and suggest that low doses of MEC may significantly enhance the efficacy of immunotherapy.

Indexed as

Receptors, NicotinicAnimalsAntibodies, MonoclonalConditioning, OperantDiscrimination LearningMaleNicotineNicotinic AntagonistsRatsRats, Sprague-DawleyUp-RegulationAntibodies, MonoclonalNicotineNicotinic AntagonistsReceptors, Nicotinic

Identifiers

PMID22503967
PMCPMC3357089
OpenAlexW2092270721

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.